Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrathiomolybdate Plus Capecitabine in High-Risk TNBC
NCT06134375Phase 2Recruiting
- Sponsor
- Dartmouth Health
- Start
- Nov 2024
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tetrathiomolybdate in triple-negative breast cancer (TNBC) (2 arms), sponsored by Dartmouth Health. Primary endpoints: Dose Limiting Toxicities at 3 years and Distant Relapse-Free Survival at 10 years. Started Nov 2024; status: recruiting.
02
Drugs
tetrathiomolybdate
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06134375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134375.